AMRI NASDAQ
Albany Molecular Research, Inc.
1W: +0.1%
1M: +0.1%
3M: +7.8%
1Y: +46.7%
3Y: +12.6%
5Y: +550.9%
$21.74
Last traded 2017-08-31 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$570M
+41.8% ▲
5Y CAGR: +22.4%
Gross Profit
$133M
+24.3% ▲
5Y CAGR: +27.7%
Operating Income
-$19M
-237.4% ▼
Net Income
-$70M
-2949.6% ▼
EPS (Diluted)
$-1.65
-2277.5% ▼
EBITDA
$37M
-19.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|
| Revenue | $227M | $247M | $277M | $402M | $570M |
| YoY Growth | +9.2% | +8.8% | +12.2% | +45.5% | +41.8% |
| Cost of Revenue | $168M | $172M | $209M | $296M | $438M |
| Gross Profit | $59M | $75M | $67M | $107M | $133M |
| Gross Margin | 25.9% | 30.3% | 24.4% | 26.6% | 23.3% |
| R&D Expenses | $906K | $414K | $1M | $5M | $16M |
| SG&A Expenses | $41M | $42M | $49M | $77M | $122M |
| Operating Expenses | $42M | $43M | $50M | $83M | $138M |
| Operating Income | $703K | $20M | $6M | $14M | -$19M |
| Operating Margin | 0.3% | 8.2% | 2.1% | 3.4% | -3.3% |
| Interest Expense | $0 | $1M | $11M | $19M | $40M |
| Income Before Tax | $119K | $20M | -$5M | -$3M | -$60M |
| Tax Expense | $4M | $7M | -$2M | -$1M | $10M |
| Net Income | -$4M | $13M | -$3M | -$2M | -$70M |
| Net Margin | -1.7% | 5.1% | -1.2% | -0.6% | -12.3% |
| EPS (Diluted) | $-0.13 | $0.40 | $-0.10 | $-0.07 | $-1.65 |
| EBITDA | $17M | $36M | $20M | $45M | $37M |
| Shares Outstanding | 30M | 32M | 32M | 33M | 42M |